Use of Direct Oral Anticoagulation for Isolated Distal Deep Vein Thrombosis in Japanese Orthopedic Patients

Ayumi Omura1, Hiroyoshi Mori1, Masahiro Sasai1

  • 1Division of Cardiology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.

Annals of Vascular Diseases
|December 27, 2024
PubMed

Insights

Direct oral anticoagulants (DOAC) showed no significant difference in embolic or bleeding events for isolated distal deep vein thrombosis (DVT) in orthopedic patients. Careful risk assessment is crucial for managing these patients.

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Orthopedic Surgery

Background:

  • Direct oral anticoagulants (DOAC) are increasingly used for venous thromboembolism.
  • Limited data exists on DOAC efficacy for isolated distal deep vein thrombosis (DVT).

Purpose of the Study:

  • To evaluate the efficacy and safety of DOAC in hospitalized orthopedic patients with isolated distal DVT.

Main Methods:

  • Retrospective study of 196 orthopedic patients diagnosed with isolated distal DVT (2016-2018).
  • Patients were followed for 1 year, comparing outcomes between DOAC and non-DOAC groups.
  • Embolic events included pulmonary embolism (PE) and DVT extension; bleeding events were classified by BARC criteria.

Main Results:

  • 84% of patients received DOAC. Embolic events occurred in 1.5% of the DOAC group vs. 0% in the non-DOAC group (p=0.443).
  • Bleeding events occurred in 5.1% of the DOAC group vs. 0% in the non-DOAC group (p=0.157).
  • Most bleeding events (80%) were in patients with HAS-BLED scores ≥3.

Conclusions:

  • No significant differences in embolic or bleeding events were observed between DOAC and non-DOAC groups in this retrospective analysis.
  • Balancing thrombotic and bleeding risks is essential for managing isolated distal DVT.